Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials
暂无分享,去创建一个
Srinivas R. Sadda | Emily Y. Chew | Paul Mitchell | Neil M. Bressler | Frank G. Holz | Sarah Gray | Barbara Tong | P. Mitchell | N. Bressler | E. Chew | L. Honigberg | S. Sadda | A. Tufail | F. Holz | J. Ehrlich | Daniela Ferrara | Sarah Gray | B. Busbee | Adnan Tufail | Daniela Ferrara | C. Brittain | Lee Honigberg | Christopher Brittain | Jason S. Ehrlich | Brandon Busbee | Jillian Martin | B. Tong | Jillian Martin | D. Ferrara
[1] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[2] R A Schuchard,et al. Landmark-driven fundus perimetry using the scanning laser ophthalmoscope. , 1995, Investigative ophthalmology & visual science.
[3] H. Müller-Eberhard,et al. Mechanism of action of factor D of the alternative complement pathway , 1978, The Journal of experimental medicine.
[4] John D Lambris,et al. Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.
[5] D L DeMets,et al. Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.
[6] S. Sadda,et al. CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2016, Retina.
[7] S. Barnum,et al. Renal filtration and catabolism of complement protein D. , 1985, The New England journal of medicine.
[8] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[9] Johanna M Seddon,et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. , 2005, Archives of ophthalmology.
[10] J S Sunness,et al. Measuring geographic atrophy in advanced age-related macular degeneration. , 1999, Investigative ophthalmology & visual science.
[11] J S Sunness,et al. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. , 1999, Ophthalmology.
[12] Wolfgang Radner,et al. The validity and reliability of short German sentences for measuring reading speed , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.
[13] E. Chew,et al. Clinical and Genetic Factors Associated with Progression of Geographic Atrophy Lesions in Age-Related Macular Degeneration , 2015, PloS one.
[14] B S Hawkins,et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. , 1997, Ophthalmology.
[15] P. Hass,et al. Complement Inhibition in Cynomolgus Monkeys by Anti–Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[16] B. Yaspan,et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration , 2017, Science Translational Medicine.
[17] Christian Simader,et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.
[18] R. Klein,et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.
[19] B. Rosner,et al. Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. , 2015, Investigative ophthalmology & visual science.
[20] Jens Dreyhaupt,et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. , 2007, American journal of ophthalmology.
[21] Kang Zhang,et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. , 2014, Ophthalmology.
[22] Benita J. O’Colmain,et al. Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.
[23] B. Gelfand,et al. Immunology of age-related macular degeneration , 2013, Nature Reviews Immunology.
[24] D. Cook,et al. Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis. , 2015, American journal of ophthalmology.
[25] A functional variant in the CFI gene confers a high risk of age-related macular degeneration , 2013 .
[26] G. Abecasis,et al. Age-related macular degeneration: genetics and biology coming together. , 2014, Annual review of genomics and human genetics.
[27] R. Nussenblatt,et al. Uveitis: Fundamentals and Clinical Practice , 1988 .
[28] Paul Mitchell,et al. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. , 2017, Ophthalmology.
[29] I. Deary,et al. Complement C3 variant and the risk of age-related macular degeneration. , 2007, The New England journal of medicine.
[30] W. Radner,et al. English sentence optotypes for measuring reading acuity and speed—the English version of the Radner Reading Charts , 2014, Graefe's Archive for Clinical and Experimental Ophthalmology.
[31] Judith Alexander,et al. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. , 1997, Archives of ophthalmology.
[32] Pradeep Ramulu,et al. Characterizing functional complaints in patients seeking outpatient low-vision services in the United States. , 2014, Ophthalmology.
[33] S. Narayana,et al. Complement factor D, a novel serine protease , 1996, Protein science : a publication of the Protein Society.
[34] Sharon D. Solomon,et al. RISK FACTORS FOR SECOND EYE PROGRESSION TO ADVANCED AGE-RELATED MACULAR DEGENERATION: SST Report No. 21 Submacular Surgery Trials Research Group , 2009, Retina.
[35] Ursula Schmidt-Erfurth,et al. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET , 2017, Retina.
[36] M. Hogan,et al. Signs and symptoms of uveitis. I. Anterior uveitis. , 1959, American journal of ophthalmology.
[37] Jennifer I. Lim,et al. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.
[38] Ronald Klein,et al. The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. , 2008, American journal of ophthalmology.
[39] Gordon E. Legge,et al. Baseline MNREAD Measures for Normally Sighted Subjects From Childhood to Old Age , 2016, Investigative Ophthalmology and Visual Science.
[40] J. Sunness. Reading newsprint but not headlines: pitfalls in measuring visual acuity and color vision in patients with bullseye maculopathy and other macular scotomas. , 2008, Retinal cases & brief reports.
[41] P. Rosenfeld,et al. Association Between Growth of Geographic Atrophy and the Complement Factor I Locus. , 2015, Ophthalmic surgery, lasers & imaging retina.
[42] G. Rubin,et al. Foveal-Sparing Scotomas in Advanced Dry Age-Related Macular Degeneration , 2008, Journal of visual impairment & blindness.
[43] Allen C Ho,et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.
[44] Jeremy Murray,et al. Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite* , 2012, The Journal of Biological Chemistry.
[45] Johannes R. Vingerling,et al. The prevalence of age-related maculopathy in the Rotterdam Study. , 1995, Ophthalmology.
[46] Cynthia A. Toth,et al. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. , 2013, JAMA.
[47] Frederick L Ferris,et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. , 2009, Archives of ophthalmology.
[48] M. Walport,et al. Complement. Second of two parts. , 2001, The New England journal of medicine.
[49] Hans Limburg,et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. , 2017, The Lancet. Global health.
[50] A. Ramé. [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.